MD Anderson Cancer Center is suing NantHealth's Patrick Soon-Shiong over 'moonshot' trademark, the Cancer Letter reports.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
Researcher Gordon Mills said assays based on his lab's Cancer Proteome Atlas project could be used to guide patient treatment within the next 18 months.
The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.
The centers will support the NCI's Genomic Data Analysis Network, which is tasked with creating tools and strategies to study large-scale genomics data.
The center plans to recruit and analyze samples from about 2,000 patients participating in solid tumor clinical trials in MD Anderson's Moon Shots program.
Single nucleus sequencing analysis of triple-negative breast tumors indicated that copy number changes occur in bursts early in tumor evolution.
Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.
The partners will investigate new strategies for using two of drugmaker's immuno-oncology agents to treat early- and advanced-stage lung cancer.
Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.